(NTLA) Intellia Therapeutics - Ratings and Ratios
CRISPR, Gene, Editing, Therapeutics, Pipeline
NTLA EPS (Earnings per Share)
NTLA Revenue
| Risk via 10d forecast | |
|---|---|
| Volatility | 203% |
| Value at Risk 5%th | 308% |
| Reward | |
|---|---|
| Sharpe Ratio | 0.01 |
| Alpha | -69.99 |
| Character | |
|---|---|
| Hurst Exponent | 0.601 |
| Beta | 2.110 |
| Drawdowns 3y | |
|---|---|
| Max DD | 88.22% |
| Mean DD | 53.14% |
Description: NTLA Intellia Therapeutics August 24, 2025
Intellia Therapeutics Inc (NASDAQ:NTLA) is a biotechnology company focused on developing innovative therapies using its proprietary CRISPR/Cas9 gene editing technology. As a US-based company in the biotechnology sub-industry, NTLAs stock performance is closely tied to advancements in its pipeline and the overall sentiment towards the sector.
The companys quarterly tax provision is a critical aspect of its financials, reflecting the tax implications of its operations and potential deferred tax assets or liabilities. Given NTLAs significant R&D expenses and lack of commercial revenue, its likely that the company is carrying substantial net operating losses (NOLs), which can be used to offset future taxable income.
Key economic drivers for NTLA include the progress of its pipeline assets, particularly its lead programs in CRISPR/Cas9-based therapies, and the competitive landscape of the gene editing space. The companys market capitalization of approximately $1.1 billion USD and a beta of 2.315 indicate a relatively high level of volatility and sensitivity to market movements. Investors should closely monitor NTLAs cash burn rate, R&D expenses as a percentage of revenue, and the advancement of its clinical trials to gauge the companys path to profitability.
From a valuation perspective, NTLAs negative P/E ratio and forward P/E ratio indicate that the company is not yet profitable. The return on equity (RoE) of -57.69% highlights the significant losses incurred by the company. As NTLA continues to invest in its pipeline, investors should focus on key performance indicators (KPIs) such as the rate of progress in its clinical trials, the expansion of its partnerships, and the development of new technologies to drive future growth.
To evaluate NTLAs potential, its essential to analyze its financial statements, particularly the income statement and cash flow statement, to understand the companys burn rate, funding requirements, and potential for future profitability. Additionally, monitoring news and announcements related to the companys pipeline progress, regulatory updates, and industry trends will be crucial in assessing the stocks potential for growth.
NTLA Stock Overview
| Market Cap in USD | 1,103m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2016-05-06 |
| Return 12m vs S&P 500 | -51.7% |
| Analyst Rating | 4.34 of 5 |
NTLA Dividends
Currently no dividends paidNTLA Growth Ratios
| CAGR | -43.57% |
| CAGR/Max DD Calmar Ratio | -0.49 |
| CAGR/Mean DD Pain Ratio | -0.82 |
| Current Volume | 13521.3k |
| Average Volume | 6972.2k |
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income (-445.8m TTM) > 0 and > 6% of Revenue (6% = 3.45m TTM) |
| FCFTA -0.45 (>2.0%) and ΔFCFTA -13.65pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 848.7% (prev 1405 %; Δ -556.0pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.44 (>3.0%) and CFO -410.6m > Net Income -445.8m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 6.21 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (110.2m) change vs 12m ago 9.09% (target <= -2.0% for YES) |
| Gross Margin 95.54% (prev 76.36%; Δ 19.18pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 5.48% (prev 3.67%; Δ 1.81pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -4.68 (EBITDA TTM -359.7m / Interest Expense TTM 78.6m) >= 6 (WARN >= 3) |
Altman Z'' -22.48
| (A) 0.53 = (Total Current Assets 581.9m - Total Current Liabilities 93.7m) / Total Assets 925.3m |
| (B) -2.70 = Retained Earnings (Balance) -2.49b / Total Assets 925.3m |
| warn (B) unusual magnitude: -2.70 — check mapping/units |
| (C) -0.35 = EBIT TTM -367.2m / Avg Total Assets 1.05b |
| (D) -14.10 = Book Value of Equity -2.49b / Total Liabilities 176.9m |
| Total Rating: -22.48 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 35.10
| 1. Piotroski 1.0pt = -4.0 |
| 2. FCF Yield -59.83% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.13 = 2.49 |
| 5. Debt/Ebitda 0.27 = 2.45 |
| 6. ROIC - WACC (= -50.02)% = -12.50 |
| 7. RoE -57.24% = -2.50 |
| 8. Rev. Trend 13.16% = 0.99 |
| 9. EPS Trend 63.59% = 3.18 |
What is the price of NTLA shares?
Over the past week, the price has changed by -25.55%, over one month by -60.32%, over three months by -9.40% and over the past year by -44.40%.
Is Intellia Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of NTLA is around 5.54 USD . This means that NTLA is currently overvalued and has a potential downside of -43.06%.
Is NTLA a buy, sell or hold?
- Strong Buy: 18
- Buy: 4
- Hold: 6
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the NTLA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 25 | 156.7% |
| Analysts Target Price | 25 | 156.7% |
| ValueRay Target Price | 6.5 | -33.3% |
NTLA Fundamental Data Overview November 11, 2025
P/S = 19.1681
P/B = 3.0677
P/EG = -0.0969
Beta = 2.11
Revenue TTM = 57.5m USD
EBIT TTM = -367.2m USD
EBITDA TTM = -359.7m USD
Long Term Debt = 210.2m USD (from capitalLeaseObligations, last fiscal year)
Short Term Debt = 27.4m USD (from shortTermDebt, last quarter)
Debt = 98.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -95.4m USD (from netDebt column, last quarter)
Enterprise Value = 689.6m USD (1.10b + Debt 98.0m - CCE 511.0m)
Interest Coverage Ratio = -4.68 (Ebit TTM -367.2m / Interest Expense TTM 78.6m)
FCF Yield = -59.83% (FCF TTM -412.6m / Enterprise Value 689.6m)
FCF Margin = -717.3% (FCF TTM -412.6m / Revenue TTM 57.5m)
Net Margin = -774.9% (Net Income TTM -445.8m / Revenue TTM 57.5m)
Gross Margin = 95.54% ((Revenue TTM 57.5m - Cost of Revenue TTM 2.57m) / Revenue TTM)
Gross Margin QoQ = 100.0% (prev 100.0%)
Tobins Q-Ratio = 0.75 (Enterprise Value 689.6m / Total Assets 925.3m)
Interest Expense / Debt = 9.02% (Interest Expense 8.83m / Debt 98.0m)
Taxrate = 21.0% (US default 21%)
NOPAT = -290.1m (EBIT -367.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.21 (Total Current Assets 581.9m / Total Current Liabilities 93.7m)
Debt / Equity = 0.13 (Debt 98.0m / totalStockholderEquity, last quarter 748.4m)
Debt / EBITDA = 0.27 (negative EBITDA) (Net Debt -95.4m / EBITDA -359.7m)
Debt / FCF = 0.23 (negative FCF - burning cash) (Net Debt -95.4m / FCF TTM -412.6m)
Total Stockholder Equity = 778.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -48.18% (Net Income -445.8m / Total Assets 925.3m)
RoE = -57.24% (Net Income TTM -445.8m / Total Stockholder Equity 778.9m)
RoCE = -37.13% (EBIT -367.2m / Capital Employed (Equity 778.9m + L.T.Debt 210.2m))
RoIC = -36.77% (negative operating profit) (NOPAT -290.1m / Invested Capital 789.0m)
WACC = 13.25% (E(1.10b)/V(1.20b) * Re(13.79%) + D(98.0m)/V(1.20b) * Rd(9.02%) * (1-Tc(0.21)))
Discount Rate = 13.79% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 10.37%
Fair Price DCF = unknown (Cash Flow -412.6m)
EPS Correlation: 63.59 | EPS CAGR: 47.58% | SUE: 0.56 | # QB: 0
Revenue Correlation: 13.16 | Revenue CAGR: 0.56% | SUE: -0.03 | # QB: 0
Additional Sources for NTLA Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle